Laboratoires Clarins

CLOSEOUT LETTER Laboratoires Clarins MARCS-CMS 568157 — January 23, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Reference #: 3002759467 Product: Drugs Recipient: Recipient Name Mr. Jonathan Zrihen Recipient Title CEO Laboratoires Clarins Clarins Group 12, avenue de la Porte-des-Ternes 75017 Paris France Issuing Office: Center for Drug Evaluation and Research | CDER United States Dear Mr. Zrihen: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-19-20 dated April 23, 2019. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Philip Kreiter Compliance Officer Division of Drug Quality II CC: Ms. Cécile Mansuy Operations Director Laboratoires Clarins 5 rue Ampére 95300 Pontoise France Content current as of: 01/27/2023 Regulated Product(s) Drugs